Results 121 to 130 of about 342 (145)

Nemolizumab

Reactions Weekly
  +9 more sources

Perforating dermatosis in a patient on haemodialysis successfully treated with nemolizumab

Clinical and Experimental Dermatology, 2023
We present a case of perforating dermatosis in a patient with uraemic pruritus who was on haemodialysis and who was successfully treated with nemolizumab, a humanized monoclonal antibody targeted against interleukin-31 receptor A. Nemolizumab may be a treatment option for perforating dermatosis with a uraemic pruritus background. To our knowledge, this
Shun, Ohmori, Yu, Sawada
openaire   +2 more sources

Nemolizumab With Concomitant Topical Therapy in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis (ARCADIA 1 and ARCADIA 2): Results From Two Replicate, Double-Blind, Randomised Controlled Phase 3 Trials

Lancet, The
BACKGROUND: Nemolizumab, an interleukin (IL)-31 receptor subunit α antagonist, inhibits the IL-31 pathway of itch and skin inflammation in atopic dermatitis.
Liliana Ulianov, Soo Yeon Cheong
exaly   +4 more sources

Comment on ‘Perforating dermatosis in a patient on haemodialysis successfully treated with nemolizumab’

Clinical and Experimental Dermatology, 2023
The pathogenesis of acquired perforating dermatosis remains unknown and management is challenging. Traditional treatment includes antihistamines, allopurinol, corticosteroids, retinoids, doxycycline, keratolytic agents and phototherapy but with limited efficacy in some patients. Recently, developments in biologics and small-molecule drugs have provided
Li-Wen, Zhang, Juan, Wu, Tao, Chen
openaire   +2 more sources

Atopic Dermatitis Flare Following Initiation of Nemolizumab

Journal of Drugs in Dermatology
Atopic dermatitis (AD) is a chronic inflammatory skin disorder marked by intense pruritus and episodic flares. While nemolizumab, an interleukin-31 (IL-31) inhibitor, has demonstrated efficacy in reducing itch severity, its broader effects on skin inflammation are not fully understood.We describe a 49-year-old male with longstanding, treatment ...
Olivia M, Burke, Jacob, Beer, Scott A, Elman   +2 more
openaire   +2 more sources

Nemolizumab (Nemluvio)

Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception ...
openaire   +1 more source

Safety Signals of Nemolizumab

Aim Nemolizumab is a novel drug used for the treatment of chronic prurigo. Using the FDA Adverse Event Reporting System (FAERS) database, this research examined adverse drug events (ADEs) related to nemolizumab in order to pinpoint potential safety signals. Methods Nemolizumab was
Xiaoting Li, Weiling Chen, Xingwu Duan
openaire   +1 more source

Nemolizumab (Nemluvio) for Atopic Dermatitis

The Medical Letter on Drugs and Therapeutics
Nemolizumab (Nemluvio – Galderma), a subcutaneously injected interleukin-31 (IL-31) receptor antagonist, has been approved by the FDA for use in combination with topical corticosteroids and/or calcineurin inhibitors for treatment of moderate to severe atopic dermatitis in patients ≥12 years old whose disease is not adequately controlled with topical ...
openaire   +2 more sources

Learning From Nemolizumab: A Promising Therapy for Prurigo Nodularis

Journal of Allergy and Clinical Immunology
Brian S Kim
exaly   +3 more sources

Use of Nemolizumab in Refractory Scrotal Dysesthesia

JAMA Dermatology
This case report describes 2 patients with refractory scrotal dysesthesia treated with nemolizumab.
openaire   +2 more sources